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Abstract
Despite improvements in critical illness survival rates with recent developments in 
medical care, many patients still have long‐term physical disabilities following stays 
in the intensive care unit (ICU). Critical illness–induced muscle weakness, so‐called 
ICU‐acquired weakness (ICU‐AW), is a common occurrence in approximately 50% of 
critically ill patients in the ICU requiring mechanical ventilation for >7 days. ICU‐AW 
 contributes to increases in duration of mechanical ventilation and lengths of ICU and 
hospital stays and may persist among survivors for several years after discharge. Risk 
factors for ICU‐AW include systemic inflammatory responses, severe sepsis, muscle 
inactivity, hyperglycemia, and use of neuromuscular blockers. Thus, the development 
of muscle wasting is suggested to be associated with pathophysiological alterations 
 leading to an imbalance between muscle proteolysis and proteosynthesis through several 
cellular signaling  networks. This chapter presents a review of the literature regarding 
critical illness–induced muscle wasting and describes potential treatment of excessive 
muscle catabolism.
Keywords: critical illness, ICU‐AW, muscle proteolysis, immobilization, neuromuscular 
electric stimulation therapy
1. Introduction
Skeletal muscle is one of the most dynamic and plastic tissues and is the largest organ in 
the body. Skeletal muscle is primarily involved in mechanical activity, which depends on 
muscle fiber contractions required for posture, physical activity, and respiratory movement. 
However, skeletal muscle is not only a component of the movement system, but it accounts for 
approximately 40% of the total body weight and contains 50–75% of all body proteins. In gen‐
eral, muscle mass depends on the balance between muscle protein synthesis and degrada‐
tion. Both processes are sensitive to a number of factors, such as nutritional status, hormonal 
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 balance, physical activity, and inflammatory stimulation. The loss of lean mass is accompa‐
nied by a concomitant loss of muscular strength, which can lead to physical  disability and loss 
of function. Muscle mass, strength, and function are also correlated with each other, and their 
decreases can lead to poor health outcomes and mortality [1].
Although the rates of survival from critical illness have improved due to recent developments 
in medical care, many patients have long‐term physical disabilities following a stay in the 
intensive care unit (ICU) [2]. Many survivors of critical illness complain of generalized muscle 
weakness, so‐called intensive care unit acquired weakness (ICUAW), for several months to 
years after discharge from hospital [3] and have persistent exercise limitations [4–6]. Severe 
neuromuscular weakness and muscle wasting often complicate recovery from critical illness.
This primary myopathy can take various morphological forms, and is assumed to be trig‐
gered by both sepsis and other factors, including the extensive use of neuromuscular block‐
ing agents and corticosteroids [7]. However, diagnosis of ICUAW is difficult in the ICU, 
because either the preexisting disorder or complications arising during the ICU stay can 
cause muscle weakness. In addition, the patient’s aggravated condition when first admitted 
to the ICU precludes careful clinical examination of ICUAW. Consequently, the attention of 
the physician is directed toward survival, and can delay diagnosis of ICUAW.
Electrophysiological investigations of peripheral nerves and muscles can help in the diagnosis 
of ICUAW at an early stage and to define prognosis, but they are time consuming and require 
the availability of skilled personnel.
Therefore, a guided approach to diagnosis is valuable. Management of ICUAW rests on support‐
ive treatment, treatment of ongoing sepsis and multiorgan failure, and control of hyperglycemia. 
Recent evidence indicates that early rehabilitation can be carried out safely and effectively to 
maintain the physical function of ICU patients, requiring little patients sedation [3].
This chapter describes the incidence rates, major risk factors, epidemiology, and electrophysi‐
ological histological features of ICUAW. Major advances in early rehabilitation and protocols 
with little or no sedation in the ICU, which improve the functional independence of patients, 
are also discussed.
2. Epidemiology
Physicians have become aware of the existence of long‐term functional impairment after ICU 
treatment. Herridge et al. [5] examined loss of muscle mass, muscle weakness, and easy fatigue 
1 year after recovery from acute respiratory distress syndrome (ARDS). Even among relatively 
young patients, half were unable to work for 1 year after discharge, and some dysfunction 
persisted even after 5 years [6]. Such disorders have been noted as ICUAW, and awareness 
regarding these issues has increased in intensive care medicine [7, 8].
ICUAW is divided into three categories: critical illness myopathy (CIM), critical illness poly‐
neuropathy (CIP), and critical illness neuromyopathy (CINM) that combines features of the 
former two conditions [9]. CIP is a pathological condition characterized by significant axonal 
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degeneration in sensory nerves, with no abnormalities in conduction velocity on electrophysi‐
ological analysis. In addition, the amplitudes of action potentials in muscle and sensory nerves 
are reduced [10]. Peripheral nerve microangiopathy due to inflammatory responses is involved 
in the pathophysiology of CIP [11, 12]. CIM is characterized by general muscle weakness and 
residual sensory function [13]. Catabolism accompanied by skeletal muscle disruption is often 
observed as the mechanism underlying its development. The muscle disorder caused by sys‐
temic inflammation and inactivity due to bed rest would be major factors [14, 15]. However, 
diagnosis of CIP and CIM is difficult because either existing disorders or complications occur‐
ring during the ICU stay causes muscle weakness. In addition, patient survival takes precedence 
in the ICU, and diagnosis of CIP and CIM is delayed or overlooked. Therefore, it is difficult 
to accurately determine the incidence rates of CIP and CIM [12, 16, 17]. Intriguingly, recent 
data suggest that CIP and CIM frequently coexist, a condition that has been termed CINM [18]. 
The pathophysiology of CINM/ICUAW is complex and includes the sequelae of bed rest, the 
effects of critical illness–induced cytokine production, and possibly the interplay of drugs, such 
as neuromuscular blocking agents and corticosteroids (Figure 1). Protein‐energy malnutrition, 
electrolyte imbalances, and glutamine deficiency also play roles in the critically ill.
Current estimates indicate that 70–80% of critically ill patients develop CIP, with a compara‐
ble percentage presumably developing CIM [16, 19, 20]. In subpopulations in which sepsis is 
complicated by multiple organ failure (MOF), the incidence rates of CIP and CIM could even 
reach 100% [20]. Approximately two‐thirds of patients with ARDS exhibit these neuromuscu‐
lar disorders [21], and in unselected patients that have required mechanical ventilation for at 
Figure 1. Pathophysiology of CINM/ICUAW. CINM, critical illness neuromyopathy; ICU, intensive care unit; ICUAW, 
ICU‐acquired weakness; NMBA, neuromuscular blocking agent; ROS, reactive oxygen species.
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least 4 days, the incidence rates of CIP and CIM range from 25 to 33% on clinical evaluation, 
and can reach 58% on electrophysiological evaluation [4, 17]. Furthermore, 49–77% of patients 
will have ICUAW when treated in an ICU for ≥7 days [22, 23].
ICUAW leads to prolonged physical disabilities that persist for months or years after ICU 
discharge [18, 24–26]. Nearly one‐third of patients with ICUAW have difficulty in recovering 
independent walking or spontaneous breathing [27]. The effects of critical illness and ICU 
stay can result in serious weakness [3]. In the CRIMYNE study, the findings from the 1‐year 
follow‐up cohort study showed that patients with CIM recovered within 6 months, whereas 
those with CIP had a slower recovery or did not recover [17]. Mortality is increased in patients 
with CIP [4, 28].
The incidences of CIP and CIM are not clear, because of the wide variation in patient pop‐
ulations, risk factors, and diagnostic criteria, as well as in the timing of assessment [29]. 
In patients with mechanical ventilation beyond 7 days and with the presence of systemic 
inflammatory response syndrome (SIRS), the incidences of CIP and CIM were 33% on clini‐
cal assessment [22] and 30–58% on electrophysiological assessment [4, 10, 21]. The incidence 
rates were 34–60% in patients with ARDS [21], 24–77% in those with ICU stay beyond 1 
week [10, 21, 22], 56–80% in those with multiorgan failure [15], and 100% in those with septic 
shock or severe sepsis [20]. A systematic review showed evidence of CIP and CIM in 46% of 
adult ICU patients that had lengthy periods of mechanical ventilation, sepsis, or multiorgan 
failure [10].
3. Risk factors for ICUAW
The ICUAW is regulated by several risk factors such as multiple organ failure, inactivity, 
hyperglycemia, corticosteroids, and neuromuscular blocking agents, although the pathogenic 
mechanism of ICUAW remains unclear (Table 1) [7, 30].
In particular, multiple organ dysfunction and immobility are important factors causing 
 muscle dysfunction in patients in critical condition.
Multiple organ failure (MOF) is the major risk factor for ICUAW, but one needs to interpret it 
carefully. Neuromuscular organ failure of sepsis is the central element of the pathological con‐
dition in ICUAW. Indeed, sepsis, SIRS, and MOF develops the CIP [31]. Other diseases caused 
by SIRS, such as sepsis, induce mitochondrial injury [32], sodium channel inactivity [33], and 
have adverse effects on neuromuscular activity. Skeletal muscle proteolysis is the main patho‐
genic mechanism of CIM [28, 34]. The specific pathology of ICUAW reflects the structural dete‐
rioration of peripheral nerves and skeletal muscles, and not only disuse muscle atrophy [35].
Immobility also facilitates muscle wasting in critical illness. The conditions of low mechanical 
load, such as bed rest, immobilization, and disuse, induce marked losses of skeletal muscle 
mass, strength, and physiological function. Disuse muscle wasting involves a complicated 
cytokine and inflammatory response. Even a short period of bed rest for 5 days will results 
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in significant decreases in the size of muscle fibers (3.5–10%) and muscle strength (9–13%) 
[36, 37]. However, as patients with ICUAW are usually under sedation, it is not clear how 
much sedation‐induced inactivity affects the condition, apart from the severity of the disease. 
Therefore, to elucidate the pathology of ICUAW, factors of inactivity should be examined 
separately. Griffiths et al. [38] performed sustained passive exercise on one lower limb in a 
patient with severe respiratory failure in neuromuscular block, and examined the effects of 
intervention using the contralateral lower limb as a control limb. The results indicated that 
muscle strength and muscle protein level were significantly higher in the intervention limb. 
Thus, ICU patients suffer from long‐term inactivity, and the methodology of physical activity 
in ICU should be reconsidered.
Diaphragmatic weakness, pulmonary injury, and atrophy develop rapidly during mechanical 
ventilation with sedation [39]. The duration of mechanical ventilation is independently associ‐
ated with severe limb weakness or electrophysiological evidence of CIP [33, 40]. Respiratory 
muscle weakness also extends mechanical ventilation duration in the ICU. Respiratory muscle 
weakness elicits infection or sepsis, disease severity, and peripheral weakness [41, 42]. These 
data also suggest that ICUAW includes respiratory muscle weakness, because the diaphrag‐
matic nerve and diaphragm also exhibit electrophysiological abnormalities similar to peripheral 
nerves and muscles [43].
Neuromuscular blocking agents and corticosteroids dose similar risks for ICUAW [44]. The 
risk of acute myopathy by the treatment with corticosteroid and neuromuscular blocking 
agent appears to increase after 24–48 hours of therapy. In addition, corticosteroids are the 
main determinants of impaired ability to exercise at 3 months in patients with critical illness 
myopathy [5]. After the first case report of profound frailty in asthma patients treated with 
corticosteroids and neuromuscular blocking agents [45], many similar findings were reported 
indicating that these two substances [28, 46] contribute to CIP/CIM or ICUAW. In animal 
studies, denervated and steroid‐treated animals showed muscle changes similar to those 
observed in critical patients [47]. However, some studies have failed to confirm the adverse 
SIRS/sepsis
Multiorgan failure
Hyperglycemia
Renal replacement therapy
Catecholamine administration
Female sex
Duration of mechanical ventilation
Corticosteroids
Neuromuscular blocking agents
SIRS, systemic inflammatory response syndrome.
Table 1. Risk factors implicated in the development of ICU‐acquired weakness.
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effects of corticosteroids [22, 28, 48] or neuromuscular blocking agents [49]. The interaction 
between these drugs and ICUAW would ascribe to use as well as to complicated relationships 
with dose, timing, and other risk factors for ICUAW.
The other independent risk factors for ICUAW identified in previous studies are disease 
 severity [22, 50], use of vasopressors and catecholamine [40], length of stay in the ICU [34, 40], 
renal failure and renal replacement therapy [50], hyperosmolality [28], parenteral nutrition 
[28], low serum albumin level [34], and neurological disorders [34]. Hyperglycemia was shown 
to be an independent risk factor for the electrophysiological and clinical signs of ICUAW, and 
increased insulin dose reduced the incidence of ICUAW [51]. Several studies indirectly dem‐
onstrated that the severity of disease is correlated with ICUAW, as reflected by acute inflam‐
matory mediators and the use of vasopressors [40, 52]. Age is also an important risk factor for 
ICUAW [51]. As hospitalization in the ICU is often unpredictable, it is difficult to confirm the 
state of muscle function before onset. The motor function before hospitalization depends on 
many factors, but the muscle strength and muscle mass before onset reflect age to some extent.
4. Critical illness–induced muscle wasting
There are at least two phases, early and late phase, in the pathophysiological process of 
 myopathy occurring in critically ill patients (Figure 2). The early phase progresses rapidly 
between the 3rd and 5th day after onset, whereas the late phase is slowly sustained from 
5 days after onset. The following section describes how sepsis and inactivity, which are the 
main factors of ICUAW, influence myopathy in each phase.
4.1. Early phase
Pathophysiologically, the initial response to severe infection is in the activation of antigen‐
presenting immune cells. This occurs via pattern recognition receptors [53–55] with other 
immune mechanisms, such as cytokine release, endothelial and complement activation, and 
release of oxygen radicals. Inflammatory cytokines [tumor necrosis factor alpha (TNF‐α), 
interleukin (IL)‐6, and IL‐1β] and complement factors (C3a and C5a) act as important media‐
tors at this stage of inflammation [54]. Inflammatory stimulation causes muscle wasting 
mainly by degradation of muscle proteins [56]. Muscle proteins break down into amino acids 
and some are used in the liver for the synthesis of glutathione and acute proteins. Muscle 
 proteins to be degraded are derived from myofibrillar proteins (actin, myosin), which account 
for 60–70% of muscle proteins [56]. Therefore, stressed patients lose 250 g/day of muscle pro‐
tein corresponding to a muscle mass between 750 and 1000 g [57].
The muscle proteolysis in the early phase is caused by several cell signaling systems, but the 
major pathway of proteolysis activated in animal models of inflammatory muscle wasting are the 
calpain system and ubiquitin‐proteasome system (UPS) (Figure 3). Calpain, a calcium‐depen‐
dent protease, is activated first [58]. In septic rats, calpain activity seems to be increased by 70% as 
measured by the degradation products of azocasein in muscle extracts [59]. Although inhibition 
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of calpain function cannot suppress muscle weight reduction, the sarcomere structure and con‐
tractile tension per unit area of muscle fibers are maintained at normal levels [60]. These findings 
suggest that the calpain system targets cytoskeletal proteins that maintain the sarcomere struc‐
ture. Activated calpain does not directly degrade contractile proteins, such as actin and myosin, 
but degrades cytoskeletal proteins, such as titin and nebulin [61]. The activity of calpastatin, a 
calpain system inhibitor, is also decreased by 40–60% in the muscles of septic rats [62]. As a result, 
myofibrils, such as actin and myosin, are released into the cytoplasm in the monomeric state.
At the next stage, activation of the UPS rapidly degrades the myofibrils. UPS is the major 
decomposition system in various myopathies causing muscle atrophy, such as inactivity, 
inflammation, cell energy stress, and malnutrition. The forkhead box O (FOXO) family of 
transcription factors stimulates the expression of two important regulators of UPS‐mediated 
proteolysis of ubiquitin ligase atrogin‐1 and muscle‐specific RING finger protein‐1 (MuRF1) 
[63–65]. In animal models, both MuRF1 and atrogin‐1 recruitment, and UPS activation, 
mainly contribute to the loss of muscle mass, such as inactivation‐induced atrophy, acute 
illness, chronic disease, and CIM [63, 66, 67]. In human studies, mRNA expression levels of 
components of the UPS are increased in septic muscle. Muscle‐specific E3 protein, MuRF1, 
and atrogin‐1 in the vastus lateralis of critical patients are elevated at both mRNA and protein 
Figure 2. Mediators of critical illness‐induced muscle dysfunction. Skeletal muscle atrophy is the most universal feature 
of the early phase, which is driven fundamentally by inflammation and disuse. Other factors, such as neuropathic injury 
and medications, can exacerbate atrophy and independently cause muscle dysfunction. Therefore, inhibiting muscle 
protein degradation is the most promising potential early‐phase therapy. The late phase is marked by cessation of 
inflammation‐induced muscle proteolysis, and therefore potential treatments at this time point will differ. Mediators of 
the late phase would involve persistence of some early‐phase injuries or a failure to regain muscle homeostasis following 
the early phase. Late‐phase dysfunction may be compounded by underlying premorbid neuromuscular defects. NMJ, 
neuromuscular junction; UPS, ubiquitin‐proteasome system.
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levels [68]. The chymotrypsin‐like peptidase activity of the membrane‐associated proteasome 
is increased by 30% in limb muscle of critical patients [69].
Similar mechanisms contribute to respiratory muscle weakness in the acute phase. MuRF1 
activity in the diaphragm is increased in critical patients under artificial respiratory man‐
agement [70]. Postoperative respiratory muscle weakness would be caused by increased 
postoperative inflammatory cytokine production [71]. Mechanical ventilation as a substitute 
for diaphragm immobility is an important trigger, especially when combined with sedation, 
leading to weakness of the diaphragm [70].
The major etiology in the acute phase of CIP may be axonal dysfunction due to membrane 
depolarization disorders [72]. A disorder of the blood‐nerve barrier is a pathogenic event 
induced in the absence of ultrastructural injury in the peripheral nerves [73]. Especially in 
peripheral nerves, the lack of autoregulation in capillary vessels leads to impairment of micro‐
circulation. When the vascular permeability is increased, edema occurs in the endoneurium 
and ischemia develops in the tissue, resulting in microcirculatory insufficiency of peripheral 
nerve vessels [72]. In particular, damage to structural proteins of axons with high energy 
demand causes CIP with axonal degeneration of peripheral nerves.
4.2. Late phase
Risk factors of muscle wasting in severe patients directly or indirectly induce muscle inactiv‐
ity. In the late phase, inactivity is the main cause of skeletal muscle contraction. Inactivity 
directly affects muscle wasting, even if there are no systemic inflammatory changes [74]. 
Figure 3. Muscle protein homeostasis in critical illness. The diagram depicts changes in protein metabolism caused by 
pathophysiological processes in critical illness, including sepsis, inflammation, and immobility. Upper circles denote 
altered regulation of major steps in protein synthesis (left) and degradation (right). PI3‐K, phosphatidylinositol‐4,5‐
bisphosphate 3‐kinase; Akt, also known as protein kinase B; mTOR, mechanistic target of rapamycin; MAPK, mitogen‐
activated protein kinase; FOXO, forkhead box‐O; Ub, ubiquitin; IRS, insulin receptor substrate.
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Some studies demonstrated the adverse effects of one‐leg suspension and casting in bed rest 
on skeletal muscle mass in humans—the muscle mass and the cross‐sectional muscle area 
were significantly decreased in the inactive leg. Muscle atrophy begins within hours of com‐
mencement of sleep and deep sedation. Muscle mass and muscular strength decline greatly 
within 10 days of rest, especially in the lower limbs, even in healthy people [75].
Anomalies in action potentials due to inactivity occur within several hours. As the general 
state of health recovers, potential anomalies readily improve [33]. However, this improve‐
ment reaches a plateau within 3–6 months, and some patients do not recover normal func‐
tion even in 1–2 years. Little is known about the pathophysiology of CIP in this latter type of 
sustained ICUAW.
Electrical nonirritability of muscle has been reported in rat denervation and steroid admin‐
istration models [76]. The primary cause of hypoexcitability of steroid‐denervated fibers is 
the combination of resting potential depolarization and hyperpolarized shift in the voltage 
dependence of NaV1.4 sodium channel inactivation [77]. Depolarization of stationary mem‐
branes causes muscle inactivity and could be an important mechanism accounting for signifi‐
cant muscle weakness during immobility [78]. Upregulation of NaV1.5 sodium channels has 
been demonstrated in the muscle of rats with chronic sepsis, suggesting that several risk fac‐
tors lead to muscle electrical nonexcitability [79]. A negative shift in sodium channel gating in 
peripheral nerves of muscle is distinguished from CIM as a characteristic disorder in CIP [80].
Recently, autophagy, a bulk degradation system of the cytoplasmic matrix, was shown to 
potently induce muscle atrophy [81]. Animal models of muscle atrophy (demyelination, 
 sepsis, starvation) show increased autophagy, and FOXO transcriptional regulators modulate 
expression of several autophagy supporting genes [82–84]. However, autophagy dysfunction 
in mice caused enhanced oxidative stress inducing myofiber protein aggregates, abnormal 
muscle mitochondrial accumulation, and myofiber degeneration [85]. Thus, titration of the 
degree of autophagy appears to be essential for maintaining healthy muscle mass. That is, 
excessive autophagic activity leads to muscle atrophy, whereas toxic products accumulate 
and lead to muscle degeneration under conditions of autophagy failure.
Some studies showed UPS activation in acute CIM and septic human atrophic skeletal muscle 
[68, 86, 87], but others showed muscle protein degradation with low levels of MuRF1/atro‐
gin‐1 [88]. These discrepancies seem to be due to the dynamics of expression of UPS compo‐
nent mediators in muscle wasting. For example, in animal models, MuRF1/atrogin‐1 mRNA 
levels increase only in short‐term denervated or unweighted muscles, but do not increase 
over a long period of time [66]. Likewise, MuRF1 mRNA expression was also increased in the 
lateral vastus muscle of healthy volunteers with short‐term rather than long‐term periods of 
inactivity [89]. In chronic complete spinal cord injury patients, there were significant reduc‐
tions in atrogin‐1, MuRF1, and myostatin mRNA levels, and in FOXO1, FOXO3a, and atro‐
gin‐1 protein levels [90]. Therefore, another pathway seems to be promoted in the late phase 
instead of UPS.
Hussain et al. [91] reported that autophagy contributes to the induction of diaphragm muscle 
proteolysis in ICU patients. Induction of autophagy increased protein oxidation and enhanced 
expression of the FOXO1 gene, but not the FOXO3A gene. Controlled mechanical ventilation 
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also triggered the inhibition of both Akt expression and FOXO1 phosphorylation. In addition, 
the decrease in mature autophagic vesicles and accumulation of p62 (a protein degraded by 
autophagy) indicated deficiency of autophagy in the muscle of critically ill patients [92]. In 
severe conditions, autophagy would be the cause of muscle atrophy, and participate in the 
mediation of acute or persistent CIM.
Nuclear import of FOXO activates both UPS and autophagy pathways, and promotes 
muscle protein degradation of myotube cells, 70% of which is due to autophagy [61]. The 
expression of autophagy‐related genes in skeletal muscle is markedly increased by fast‐
ing and denervation, and autophagy appears to be an important degradation system for 
chronic muscle atrophy in sarcopenia and cachexia [93]. In addition, FOXO and p38 mito‐
gen‐activated  protein kinase (MAPK) induce expression of the muscle‐specific E3 gene 
as well as expression of the autophagy‐related gene Atg7 [94]. Furthermore, autophagy‐
related molecules, such as Beclin‐1 and LC3‐II proteins, are elevated in skeletal muscle 
under denervation for 7 days [95]. The elevated levels of LC3 and Beclin‐1 mRNA expres‐
sion were also reported in skeletal  muscle after 3 or 7 days of denervation [64]. Under 
such conditions of inactivity, such as the late phase, autophagy seems to modulate muscle 
atrophy accompanying inactivity [96].
Critically ill patients lose muscle as a result of an inability to maintain rates of protein 
synthesis above those of protein breakdown [97]. Decline in muscle protein synthesis is 
observed very early in the period of inactivity. Studies using inactivity models, such as 
rat tail suspension and casting fixation, suggest that muscle protein synthesis declines 
rapidly within 6–24 hours after commencement of inactivity and that level is maintained 
during inactivity [98]. Therefore, the decrease in muscle protein synthesis contributes to 
muscle atrophy in the very early stages of inactivity. Insulin‐like growth factor‐1 (IGF‐1) 
secreted from skeletal muscle along with physical activity binds to the IGF‐1 receptor 
and promotes the activation of PI3K‐Akt‐mammalian target‐mediated signaling of the 
rapamycin (mTOR) pathway. Subsequently, protein synthesis is promoted through phos‐
phorylation of p70S6K involved in the initiation of downstream translation and inactiva‐
tion of the translational repressor factor 4E‐BP1. The PI3K/Akt pathway is an important 
network known to induce muscle protein synthesis and muscle growth [60]. Interestingly, 
Akt activation has been shown to block the progression of FOXO nuclear translocation 
and atrophy, demonstrating mutual signaling between muscle atrophy and hypertrophy 
induction [99].
The levels of Akt1, mTOR, p70S6K, and 4E‐BP1 phosphorylation in the soleus muscle of 
rats are decreased by tail suspension for 7 days [100]. Signaling pathways regulating muscle 
protein synthesis are repressed in critically ill patients. For the mTOR pathway, a sepsis 
model showed interference with protein translation and inhibition of protein synthesis [101]. 
Protein phosphorylation was decreased for all signaling proteins of Akt1, PKB, GSK3, mTOR, 
p70S6K, and 4E‐BP1 in a study of vastus lateralis muscle biopsies in 10 critical patients [86]. 
Therefore, in inactive skeletal muscles in which mechanical stress is relieved, decreases in 
IGF‐1/PI3K/Akt signals cause reductions in muscle protein synthesis. These findings indi‐
cate that the  signal transduction activity promoting protein translation is reduced in inactive 
patients.
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5. Interventions for ICUAW
Effective interventions for ICUAW have not yet been established. As a strategy, avoiding or 
diminishing iatrogenic risk is of primary importance [44]. Risk factors for the occurrence of 
ICUAW include sepsis, hyperglycemia, inactivity, malnutrition, corticosteroids, and the use 
of neuromuscular blockers. All of these are risk factors causing hypercatabolic states, and 
avoiding these factors is a useful intervention strategy for muscle dysfunction.
5.1. Intensive insulin treatment
Several Randomized controlled trials (RCTs) have been reported for glycemic control in the 
ICU [102–104]. Many large clinical trials indicated that hyperglycemia should be avoided 
[105]. Increases in insulin resistance causing hyperglycemia occur frequently in critically ill 
patients, and are more apparent in CIM patients [106]. As a mechanism, GLUT‐4 translocation 
impairment to myocytes would decrease glucose supply in patients. In a study based on mus‐
cle biopsy specimens, intensive insulin therapy (IIT) improved insulin resistance and GLUT‐4 
translocation in skeletal muscle [107]. RCT was performed to evaluate the effects of IIT (gly‐
cemic target 80–110 mg/dl) on neuromuscular function in ICU patients. IIT reduced the inci‐
dence of severe CIP from 49 to 25% in electrophysiological screening studies of long‐term 
hospitalized surgery patients [40]. In another study, ITT decreased the duration of mechanical 
ventilation [108]. The relative risk for developing CIP by IIT was 0.65 (95% confidence interval 
0.55–0.77) [44]. Its effect was ascribed to glycemic control rather than insulin dose [40], and it 
was observed only in patients in whom blood glucose was controlled within the normal range 
[103]. Similar findings were obtained in a retrospective study on the incidence of electrophysi‐
ological abnormalities before and after IIT [109].
On the other hand, Derde et al. [110], using muscle biopsy samples, demonstrated that IIT 
does not affect myofiber size, myofibrillar protein synthesis ability, or muscle proteolytic 
markers. ITT is considered to primarily have a neuroprotective role [107], but no neurological 
data are available. In the NICE SUGAR trial, it was questionable whether the blood glucose 
level should be strictly controlled within the normal range as a general treatment in critical 
care patients. In addition, intervention of IIT in critically ill patients increases the incidence of 
hypoglycemia and mortality rate [102]. These results would be due to methodological differ‐
ences among the trials [111]. A strategy to reduce hyperglycemia without the risk of hypogly‐
cemia is appropriate to reduce the incidence of ICUAW.
5.2. Early mobilization
In both the early and late phase, bed rest and mechanical unloading induce catabolism, mus‐
cle atrophy, and weakness. Therefore, minimizing the duration of inactivity would reduce the 
incidence of ICUAW [112, 75].
The first step to shorten the duration of inactivity is to reduce sedation. Reducing seda‐
tion seems to have a number of beneficial effects, including shortened period of mechanical 
 ventilation and ICU stay, and lessened delirium [113]. However, there have been no studies 
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of its role in prevention of muscle function decline. Reduction of sedation could contribute to 
early mobilization in critically ill patients. The combination of approach to minimize sedation 
and early mobilization was investigated in critically ill patients with long‐term mechanical 
ventilation [114]. Early mobilization and standard treatment were compared in 104 patients 
that received daily sedation interruption. Early mobilization improves exercise function at dis‐
charge, and shortens the duration of delirium and the duration of mechanical ventilation [114]. 
As there was no significant decrease in the incidence of ICUAW, reducing sedation would not 
improve the muscle strength itself but would help the patient to exercise efficiently.
To shorten the length of inactivity, early rehabilitation is carried out even with the use of 
a life‐support device, such as mechanical ventilator or left ventricular assist device. There 
have been several reports that early rehabilitation is safe and feasible even in the early phase 
in the ICU, and is beneficial for reducing ICU and hospital stay [115, 116]. RCT comparing 
“cycling exercise 20 minutes at the bedside every day” and “standard physical therapy” 
during ICU stay did not report the occurrence of muscle weakness, but the isometric knee 
extensor strength and 6‐minute walking distance were significantly higher in the intervention 
group [117].
However, there are several barriers to early rehabilitation, which may prevent the penetra‐
tion of this approach [116, 118]. Although many ICUs have successfully implemented early 
rehabilitation into routine clinical care, widespread implementation remains low, with only 
8–12% of mechanically ventilated patients mobilized out of bed as reported in two large mul‐
tisite point prevalence studies [119, 120]. Although it is impossible to change illness severity 
and consciousness level of the patient, sedation levels [121] and intentions for treatment of 
therapists [122] can be corrected appropriately. For implementation of rehabilitation, appro‐
priate protocols in the ICU are necessary to confirm the balance between beneficial effects and 
risk of mobilization, and to select the correct treatment intensity for the patients.
A study of 49 people that were not weaned from the ventilator for at least 14 days showed that 
whole‐body rehabilitation and respiratory muscle training could improve muscular strength, 
ventilator weaning, and functional status [123]. Intriguingly, Connolly et al. [124] reported 
that rehabilitation after discharge is beneficial. Physical therapy during the recovery phase in 
ICUAW plays an important role, as the disuse syndrome during the late phase and anabolic 
resistance are added to the muscle dysfunction following early phase. As this problem has not 
been resolved, it is unclear how much such a strategy will promote recovery from ICUAW.
5.3. Neuromuscular electrical stimulation
Critically ill patients in the ICU have unstable cardiopulmonary dynamics and mental state, 
and in some cases are controlled by ventricular assist devices or hemodialysis. Therefore, not 
all patients undergo active physical activity. Under these restrictions, neuromuscular electri‐
cal stimulation (NMES), which involves muscle contraction by outside electrical stimulation, 
is used.
Some studies indicated the effects of NMES on patients in the ICU. In septic patients with 
mechanical ventilator management, NMES was applied to one lower limb and the other was 
used as a control limb. Muscle strength and muscle protein synthesis were improved more on 
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the stimulated side limb, although the muscle cross‐sectional area and muscle mass decreased 
in both limbs [125, 126]. A previous RCT using NMES indicated increased muscle strength 
and decreased mechanical ventilator duration and the incidence of ICUAW decreased from 
39.3 to 12.5% in the NMES intervention group [127].
NMES intervention for Chronic obstructive pulmonary disease (COPD) patients under 
mechanical ventilation improved the muscle strength and reduced the number of days 
needed to transfer from bed to chair [128]. Another RCT in COPD patients within the ICU 
did not show the occurrence of ICUAW in patients treated with NMES [129]. In addition, in 
the NMES group, the quadriceps muscle strength measured with a dynamometer and the 
walking distance were increased [130]. Although not performed in patients in the ICU, NMES 
intervention was shown to increase muscle strength and exercise tolerance [131]. NMES for 
critically ill patients in the ICU would ameliorate muscle weakness and improve mobility 
[132, 133].
Several basic studies examined the direct effects of NMES on muscle function in the ICU. 
Factors of muscle dysfunction, such as ICUAW, include neuropathy and muscle protein deg‐
radation caused by inflammation, peripheral microcirculation disorder, increased insulin 
resistance, and abnormal energy metabolism due to mitochondrial dysfunction [134]. NMES 
improves these factors that promote muscle catabolism [135–139]. In addition, NMES for 
patients undergoing cardiac surgery reduced the postoperative excretion of 3‐methylhistidine 
as an indicator of muscle proteolysis [140]. A preliminary study using muscle biopsy speci‐
mens from patients at risk for ICUAW indicated that NMES could improve AMPK activation, 
glucose utilization, and GLUT‐4 translocation [106].
Taken together, these findings indicated that NMES can inhibit catabolism and promote the 
anabolic pathway (Figure 4). As NMES can stimulate muscle contraction quantitatively and 
independent of intention in the patient, performance of NMES from the early phase is the 
most effective intervention for ICUAW. However, NMES research data should be interpreted 
carefully because of significant differences in baseline characteristics among patients, includ‐
ing APACHE II score and certain comorbidities [141]. There are several methodological prob‐
lems, such as small sample size and incomplete results, and therefore these findings should be 
confirmed in large‐scale trials. Although the amount of stimulation is unclear, it is important 
to maintain muscle contraction even at the early phase of critical illness.
5.4. Nutritional strategies
Malnutrition develops rapidly in critically ill patients due to dysfunction of the gastrointes‐
tinal tract. Hence, rich nutrition management in the acute phase may be considered, but the 
scientific evidence is not yet clear.
Although patients undergoing esophagectomy or pancreaticoduodenectomy did not 
receive enteral nutrition during the 6 days postoperatively, there were no significant dif‐
ferences in grip strength, respiratory muscle strength, or recovery of walking ability, com‐
pared with nutritionally fed patients after jejunostomy [142]. In the EPaNIC study, 4640 
patients were randomized to early parenteral replacement therapy (early PN group) or 
tolerating caloric deficiency for first week in ICU (late PN group) [143]. The late PN group 
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showed promotion of recovery, decreased mechanical ventilator duration, and reduced 
complications compared to the early PN group. In addition, whole‐body muscle strength 
assessment using the Medical research council scores was performed in patients predicted 
to be at high risk of developing ICUAW [144]. Evaluation of muscle strength was conducted 
three times a week from day 8 until ICU discharge or death. The incidence of ICUAW 
was significantly lower in the late PN group compared with the early PN group. In the 
muscle biopsy specimens of 122 patients with EPaNIC, LC3II and LC3I ratios associated 
with autophagosome formation were higher in patients in the late PN group than the early 
PN group [144]. This study indicated that the muscle fiber autophagy pathway was more 
efficient in the late PN group.
Another large RCT was performed in 1372 ICU patients to compare conventional man‐
agement with early parenteral nutrition. This study indicated a greater degree of muscle 
wasting in patients under conventional management [145]. The Eden trial examined enteral 
nutritional management versus nutritional feeding in 1000 ICU patients with acute lung 
injury [146]. At 6‐ and 12‐month follow‐up, the physical abilities of 174 survivors were sig‐
nificantly lower than the predicted values. However, no significant differences were found 
in MRC total score, grip strength, maximum inspiratory pressure, 6‐minute walking dis‐
tance, or quality of life between the two groups [147]. Therefore, high energy intake from 
the early phase showed no evidence of improved physical function, but rather may worsen 
muscle wasting.
Figure 4. Suggested beneficial effects of neuromuscular electrical stimulation (NMES) with regard to muscle 
hypertrophy, atrophy, aerobic capacity, membrane excitability, and membrane translocation of GLUT4. NMES may 
preserve membrane excitability. Membrane translocation of GLUT4 is regulated by IGF‐1, AMPK, PGC‐1α, and its 
downstream targets, which may all be affected by NMES. Atrophy gene expression (MuRF‐1, atrogin‐1) increases upon 
dephosphorylating of FOXO3 transcription factors, which is inhibited by downstream insulin signaling.
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Treatment with various supplemental nutritional components has been studied. Glutamine 
concentrations in plasma and skeletal muscle are low in critical patients and are independent 
predictors of mortality [57]. Glutamine is an essential amino acid and its supplementation 
improves muscle function [57, 148]. A meta‐analysis of glutamine supplementation in criti‐
cally ill patients reported beneficial effects on prognosis [149]. In contrast, two RCTs indicated 
no such effect of glutamine supplementation [150, 151]. Although the effects on muscle func‐
tion have not been studied, an increase was observed in mortality in critical patients with 
multiple organ failure [151]. The use of other micronutrients against oxidative stress is sensi‐
ble from the pathophysiological point of view. Two meta‐analyses concluded that antioxidant 
micronutrients may be beneficial for critically ill patients [152, 153]. Preliminary data from 
animal studies indicated that mitochondrial reactive oxygen species (ROS) is an important 
factor in the progression of diaphragm atrophy and contractile dysfunction occurring during 
mechanical ventilation [154]. However, the effects on muscle weakness were not examined, 
and a recent large RCT showed no beneficial effect of antioxidants in critical patients with 
multiple organ failure [151]. Therefore, early nutritional therapies enriched with immuno‐
modulatory nutrients would not reduce the incidence of ICUAW compared with standard 
nutritional therapy for critically ill patients [155].
6. Summary and future directions
ICUAW is a common complication and an important contributor to the physical disabilities 
persisting in ICU survivors. Although various interventions have been used to prevent the 
adverse effects of ICUAW, no established therapy is available. Early rehabilitation can be an 
important preventative therapy for ICUAW. “Silent muscle” in the early phase of ICUAW 
leads to muscle catabolism through the protein degradation signaling pathway. Strategies 
aimed at minimizing the duration of immobilization would contribute to the suppression 
of muscle wasting during critical illness. Promotion of intermittent muscle contraction, such 
as NMES, would mitigate the severity and incidence of muscle wasting. Sakuma et al. [156] 
reported that resistance training combined with amino acid‐containing dietary supplements 
would be the best way to prevent the muscle wasting and weakness, including sarcopenia. 
This proposal can also be applied to preventive strategies for ICUAW, especially in the late 
phase. Further research is required to design novel rehabilitation strategies for initiating ana‐
bolic reaction and improving muscle function in patients that cannot actively participate in 
physical therapy in the acute phase of critical illness.
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